Kraj: Kanada
Język: angielski
Źródło: Health Canada
TERAZOSIN HYDROCHLORIDE
MYLAN PHARMACEUTICALS ULC
G04CA03
TERAZOSIN
5MG
TABLET
TERAZOSIN HYDROCHLORIDE 5MG
ORAL
100
Prescription
ALPHA-ADRENERGIC BLOCKING AGENTS
Active ingredient group (AIG) number: 0121210001; AHFS:
CANCELLED POST MARKET
2016-06-28
_ _ _ _ _Page 1 of 39_ PRODUCT MONOGRAPH PR MYLAN-TERAZOSIN Terazosin Hydrochloride Tablets 1 mg, 2 mg 5 mg and 10 mg Antihypertensive Agent Symptomatic Treatment of Benign Prostatic Hyperplasia (BPH) Mylan Pharmaceuticals ULC 85 Advance Road Etobicoke, ON M8Z 2S6 Date of Revision: November 17, 2014 Submission Control No: 179465 _ _ _ _ _Page 2 of 39_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 3 SUMMARY PRODUCT INFORMATION ....................................................................... 3 INDICATIONS AND CLINICAL USE ............................................................................. 3 CONTRAINDICATIONS .................................................................................................. 4 WARNINGS AND PRECAUTIONS ................................................................................. 4 ADVERSE REACTIONS ................................................................................................. 10 DRUG INTERACTIONS ................................................................................................. 13 DOSAGE AND ADMINISTRATION ............................................................................. 14 OVERDOSAGE ............................................................................................................... 16 ACTION AND CLINICAL PHARMACOLOGY ........................................................... 16 STORAGE AND STABILITY ......................................................................................... 19 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................ 19 PART II: SCIENTIFIC INFORMATION ............................................................................... 20 PHARMACEUTICAL INFORMATION ......................................................................... 20 CLINICAL TRIALS ......................................................................................................... 21 DETAILED PHARMACOLOGY . Przeczytaj cały dokument